Diabetes Clinical Trial
Official title:
Blood Glucose Differences Between Left Arm and Right Arm Using a Continuous Glucose
| NCT number | NCT04102657 |
| Other study ID # | 20-04 |
| Secondary ID | |
| Status | Recruiting |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | September 20, 2019 |
| Est. completion date | November 2019 |
Interest in continuous glucose monitors (CGMs) is growing for use in evaluating real time
glucose levels and in detecting extreme high and low values. A CGM is a small device
primarily placed on the patient's upper arm or abdomen to measure glucose at frequent time
intervals. While the accuracy of these devices is researched extensively, there are no
large-scale studies evaluating the differences in the right and left arm in terms of device
placement. In addition, intermittent fasting has gained popularity due to potential health
benefits including reductions in weight, cholesterol, and blood glucose. However, there
remains a shortage of studies researching the effect of short-term intermittent fasting on
body fat.
The purpose of this study is to see if there is a difference between glucose levels in the
right arm and left arm and to examine if short-term intermittent fasting may impact an
individual's body fat percentage.
| Status | Recruiting |
| Enrollment | 46 |
| Est. completion date | November 2019 |
| Est. primary completion date | November 2019 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 65 Years |
| Eligibility |
Inclusion Criteria: - Adults 18-65 years of age - Willing to wear CGM device for 12-14 days on both arms - Have active health insurance - Willing to refrain from any heat therapy for the duration of the study - Having an interest to comply with the fasting requirements of the study as appropriate - Willingness to maintain once daily email responses Exclusion Criteria: - Any active dermatologic condition on the upper arms - Implanted medical devices (i.e. pacemaker) - Critically ill or dialysis patients - Planned magnetic resonance imaging screening, computed tomography scan, x-ray imaging or high-frequency electrical heat treatment during study period - Current systemic infections - Subjects who are unable to fully understand the study or consent process will not be included in the study due to the lack of a qualified medical translator - Refusal to sign the informed consent document - Pregnant, planned-pregnancy in the next 30 days, or breast-feeding - Active eating disorder - Taking any medications that have an increased risk of hypoglycemia (e.g. sulfonylureas, insulin, thiazolidinediones) as determined by the primary investigators - Taking medications for obesity - You have one of the following medical conditions that can cause rapid weight loss: rheumatoid arthritis, hyperthyroidism, irritable bowel syndrome, cancer, HIV, active tuberculosis, Addison's disease - In an active weight loss program - On a specialized diet (e.g. Weight Watchers, ketogenic diet, Atkins diet) - Completed a specialized diet in the past 2 weeks (e.g. Weight Watchers, ketogenic diet, Atkins diet) - History of adverse events (i.e. shaking, dizziness, fatigue, fainting) during any prior fasting experience - Below the age of 18 years and above the age of 65 years |
| Country | Name | City | State |
|---|---|---|---|
| United States | University of the Pacific | Stockton | California |
| Lead Sponsor | Collaborator |
|---|---|
| University of the Pacific |
United States,
2. Food and Drug Administration. Self-monitoring blood glucose test systems for over-the-counter use—guidance for industry and food and drug administration staff. Available at: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM380327.pdf. Accessed October 10, 2016.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Beck RW, Hirsch IB, Laffel L, Tamborlane WV, Bode BW, Buckingham B, Chase P, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Huang ES, Kollman C, Kowalski AJ, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer SA, Wilson DM, Wolpert H, Wysocki T, Xing D. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009 Aug;32(8):1378-83. doi: 10.2337/dc09-0108. Epub 2009 May 8. — View Citation
Moro T, Tinsley G, Bianco A, Marcolin G, Pacelli QF, Battaglia G, Palma A, Gentil P, Neri M, Paoli A. Effects of eight weeks of time-restricted feeding (16/8) on basal metabolism, maximal strength, body composition, inflammation, and cardiovascular risk factors in resistance-trained males. J Transl Med. 2016 Oct 13;14(1):290. — View Citation
Rodbard D. Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities. Diabetes Technol Ther. 2016 Feb;18 Suppl 2:S3-S13. doi: 10.1089/dia.2015.0417. Review. — View Citation
Shapiro AR. Nonadjunctive Use of Continuous Glucose Monitors for Insulin Dosing: Is It Safe? J Diabetes Sci Technol. 2017 Jul;11(4):833-838. doi: 10.1177/1932296816688303. Epub 2017 Mar 1. — View Citation
Stote KS, Baer DJ, Spears K, Paul DR, Harris GK, Rumpler WV, Strycula P, Najjar SS, Ferrucci L, Ingram DK, Longo DL, Mattson MP. A controlled trial of reduced meal frequency without caloric restriction in healthy, normal-weight, middle-aged adults. Am J Clin Nutr. 2007 Apr;85(4):981-8. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Difference in time-matched glucose levels between the right arm and left arm | 12-14 days | ||
| Primary | Difference in body-fat percentage before and after 12-14 days of designated diet | 12-14 days | ||
| Secondary | Difference in glucose readings between the right arm and left arm before and after 20-minutes of unilateral arm exercise | 12-14 days | ||
| Secondary | Difference in glucose readings between the right arm and left arm per designated diet | 12-14 days | ||
| Secondary | Change in Body Mass Index before and after 12-14 days of designated diet | 12-14 days | ||
| Secondary | Change in Body Fat Analysis before and after 12-14 days of designated diet | 12-14 days | ||
| Secondary | Difference in percent of total glucose readings in hypoglycemic range (Interstitial BG <70mg/dL) between the right arm and left arm | 12-14 days | ||
| Secondary | Difference in percent of total glucose readings in euglycemic range (Interstitial BG 70mg/dL-180mg/dL) between the right arm and left arm | 12-14 days | ||
| Secondary | Difference in percent of total glucose readings in hyperglycemic range (Interstitial BG >180mg/dL) between the right arm and left arm | 12-14 days | ||
| Secondary | Difference in percent of total glucose readings in hypoglycemic range (Interstitial BG <70mg/dL) between designated diet groups | 12-14 days | ||
| Secondary | Difference in percent of total glucose readings in euglycemic range (Interstitial BG 70mg/dL-180mg/dL) between designated diet groups | 12-14 days | ||
| Secondary | Difference in percent of total glucose readings in hyperglycemic range (Interstitial BG >180mg/dL) between designated diet groups | 12-14 days | ||
| Secondary | Time in range (Interstitial BG 70mg/dL-180mg/dL) between the right arm and left arm | 12-14 days | ||
| Secondary | Time below range (Interstitial BG <70 mg/dL) between the right arm and left arm | 12-14 days | ||
| Secondary | Time in range (Interstitial BG 70mg/dL-180mg/dL) between designated diet groups | 12-14 days | ||
| Secondary | Time below range (Interstitial BG <70 mg/dL) between designated diet groups | 12-14 days |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05594446 -
Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
|
||
| Completed |
NCT03975309 -
DHS MIND Metabolomics
|
||
| Completed |
NCT01855399 -
Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes
|
N/A | |
| Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
| Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
| Recruiting |
NCT05007990 -
Caregiving Networks Across Disease Context and the Life Course
|
||
| Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
| Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
| Completed |
NCT04903496 -
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
|
||
| Completed |
NCT01437592 -
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
| Completed |
NCT03390179 -
Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
|
||
| Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
| Recruiting |
NCT05294822 -
Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes
|
N/A | |
| Completed |
NCT04427982 -
Dance and Diabetes/Prediabetes Self-Management
|
N/A | |
| Completed |
NCT02356848 -
STEP UP to Avert Amputation in Diabetes
|
N/A | |
| Completed |
NCT03292185 -
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT05477368 -
Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes
|
N/A | |
| Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 |